Cargando…
Use of Drug Claims Data and a Medication Risk Score to Assess the Impact of CYP2D6 Drug Interactions among Opioid Users on Healthcare Costs
Cytochrome P450 2D6 (CYP2D6) activity is highly variable due to several factors, including genetic polymorphisms and drug-drug-gene interactions. Hydrocodone, oxycodone, codeine, and tramadol the most commonly prescribed CYP2D6-activated opioids for pain. However, the co-administration of CYP2D6 int...
Autores principales: | Michaud, Veronique, Bikmetov, Ravil, Smith, Matt K., Dow, Pamela, Darakjian, Lucy I., Deodhar, Malavika, Cicali, Brian, Bain, Kevin T., Turgeon, Jacques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622634/ https://www.ncbi.nlm.nih.gov/pubmed/34834526 http://dx.doi.org/10.3390/jpm11111174 |
Ejemplares similares
-
Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy
por: Al Rihani, Sweilem B., et al.
Publicado: (2020) -
Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models
por: Al Rihani, Sweilem B., et al.
Publicado: (2021) -
Adverse drug event risk assessment by the virtual addition of COVID‐19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study
por: Smith, Matt K., et al.
Publicado: (2021) -
Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
por: Deodhar, Malavika, et al.
Publicado: (2020) -
Disease-Induced Modulation of Drug Transporters at the Blood–Brain Barrier Level
por: Al Rihani, Sweilem B., et al.
Publicado: (2021)